Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,091.52 -40.05 -1.28%
FTSE 100 6,541.61 -42.15 -0.64%
DAX 9,173.71 -165.46 -1.77%
Ticker Volume Price Price Delta
NIKKEI 14,387.45 390.64 2.79%
TOPIX 1,163.73 27.64 2.43%
HANG SENG 22,819.09 147.83 0.65%


(The following press release from Bayer AG was received by e-mail. It was not confirmed by the sender.)

Dear Newsletter Subscriber,

The following news item has been released:

Further milestone to becoming a leading provider of integrated crop solutions: Bayer CropScience acquires Germany-based biocontrol company Prophyta GmbH

Monheim, January 8, 2013 - Bayer CropScience has signed an agreement to acquire Prophyta GmbH, a leading supplier of microbial crop protection products headquartered in Malchow on the island of Poel in Mecklenburg-Vorpommern, Germany, along with the company´s R&D laboratories and its state-of-the-art production and formulation facilities in Wismar, Germany. The acquisition further complements Bayer CropScience´s portfolio and will help the company build a leading offer of integrated crop solutions based on high-value seeds, innovative crop protection solutions and customized services. Closing is expected within a few weeks. Financial details were not disclosed.

"This acquisition not only further strengthens our successful fruits and vegetables business," said Dr. Rüdiger Scheitza, Member of the Board of Management of Bayer CropScience AG and Head of Strategy & Business Management. "Prophyta´s patented solid-state fermentation technology and strong expertise in the formulation of live fungal spores will also help us bringing new, innovative solutions to market." Prophyta will expand Bayer CropScience´s existing biological pest control portfolio and allow the company to further leverage its technology platform acquired through Athenix Corporation and AgraQuest.

"We are proud to become part of Bayer CropScience," commented Prophyta Managing Director Dr. Peter Lüth. "Our comprehensive production and formulation capacities will help Bayer CropScience to supply its worldwide customers with large quantities of biologics based on natural fungal micro-organisms." This acquisition also opens up many opportunities for innovation in the area of Research & Development as well as growth within the Bayer CropScience Marketing & Sales network.

Prophyta, founded in 1992, offers customers well-established products primarily based on biological control agents which are registered in more than 30 countries worldwide. Key brands are Contans™ for control of Sclerotinia and the nematicide BioAct ™. Furthermore, Prophyta has developed a unique solid-state fermentation technology for production and bioprocess development of filamentous fungi. Using this patented technology, large quantities of fungal biomass as well as fungal spores can be produced under axenic conditions. Prophyta employs a total staff of approximately 30 full-time employees.

About Bayer CropScience Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer CropScience, the subgroup of Bayer AG responsible for the agricultural business, has annual sales of EUR 7.255 billion (2011) and is one of the world’s leading innovative crop science companies in the areas of seeds, crop protection and non-agricultural pest control. The company offers an outstanding range of products including high value seeds, innovative crop protection solutions based on chemical and biological modes of action as well as an extensive service backup for modern, sustainable agriculture. In the area of non-agricultural applications, Bayer CropScience has a broad portfolio of products and services to control pests from home and garden to forestry applications. The company has a global workforce of 21,000 and is represented in more than 120 countries. This and further news is available at:

Find more information at

Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This press release is available here:

Yours BayNews Editorial Team

Bayer AG Communications Building W11 51368 Leverkusen, Germany


Further news releases you can find here:

N.B. This is an automatically generated e-mail which you cannot reply to. If you have any questions, please send us an e-mail via our contact form:


© Bayer AG, 51368 Leverkusen, Germany.

All rights reserved. The entire contents, including images, graphics, animations etc., of this e-mail and the server are copyrighted.

Board of Management: Marijn Dekkers, Chairman | Werner Baumann, Wolfgang Plischke, Richard Pott Chairman of the Supervisory Board: Werner Wenning Registered office: Leverkusen | Local Court of Cologne, HRB 48248

Sponsored Links
Sponsored Links